Table 2.
Treatment details for patients with 1-year follow-up swabs
| IBD category | Treatments | |
|---|---|---|
| CD | UC | |
| n [%] | 36 | 12 |
| Treatments used in first 3 months following diagnosis, n [%] | ||
| EEN | 32 [89] | — |
| 5-ASA | 6 [17] | 11 [92] |
| Steroids | 5 [14] | 5 [42] |
| Antibiotics | 8 [22] | 1 [8] |
| Anti-TNFα drugs | 12 [33] | 3 [25] |
| Immunomodulators | 21 [58] | 1 [8] |
| Treatments at time of 1-year follow-up swab, n [%] | ||
| 5-ASA | 6 [17] | 11 [92] |
| Steroids | — | 2 [17] |
| Antibiotics | — | — |
| Anti-TNFα drugs | 16 [44] | 3 [25] |
| Immunomodulators | 24 [67] | 3 [25] |
| Disease activity at 1-year follow-up swab [per PCDAI or PUCAI], n [%] | ||
| Remission | 27 [75] | 9 [75] |
| Mild | 8 [22] | 2 [17] |
| Moderate | 1 [3] | 1 [8] |
| Severe | — | — |
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn;s disease; EEN, exclusive enteral nutrition; 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor; PCDAI, Pediatric Crohn’s Disease Activity Index; PUCAI, Pediatric Ulcerative Colitis Activity Index.